Latest News - Amgen
Top Corporates Hub
Amgen
How Much Would It Take To Earn $100 A Month From Amgen Stock
05.09.2025 03:00
Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide. It will report its Q3 2025 earnings on Oct. 29. Wall Street analysts expect the company to post EPS of $5.05, down from $5.58 in the prior-year ...
Amgen Inc. (AMGN)’s Experimental Obesity Drug MariTide Shows Up to 20% Weight Loss Potential
02.09.2025 08:29
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Amgen Inc. is one of them, Amgen Inc. (NASDAQ:AMGN), the California-based biotech giant, continues to strengthen its leadership in cardiovascular, oncology, respiratory, and rare diseases while expanding into new therapeutic frontiers. In Q2 2025, the company posted a […]
Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management
26.08.2025 17:26
Amgen (AMGN) recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings growth, with Q2 revenue rising to $9,179 million. Despite a 3% price increase over the last quarter, the overall market showed a 15% annual growth trend, which suggests that Amgen’s developments in expanding product approvals and strong earnings may have contributed positively, aligning...
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
21.08.2025 09:38
Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices.
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
19.08.2025 12:00
CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
14.08.2025 13:40
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
13.08.2025 13:33
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh
5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call
13.08.2025 03:59
Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its portfolio and notable volume growth, particularly in general medicine, rare diseases, and oncology. CEO Robert Bradway highlighted that 15 products achieved double-digit sales growth, attributing momentum to broad-based execution and continued expansion in both established and emerging therapeutic areas. However, despite these operational highlights, management acknowledged the o
AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism
13.08.2025 03:43
Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.
Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.
11.08.2025 06:00
While Celgene was absorbed by Bristol Myers in early 2019, Gilead Sciences has emerged as the enduring standout among the remaining trio. Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively. Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.
NRG Energy, Amgen, Arista Networks: Trending Tickers
06.08.2025 20:01
NRG Energy (NRG) stock falls after its 295MW Texas data center deal underwhelmed investors. Amgen (AMGN) stock dips as investors focus on uncertainties around its obesity drug, MariTide, despite a second quarter beat. Arista Networks (ANET) hits record highs after strong second quarter results and an upbeat third quarter forecast. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Amgen Stock Sinks As Market Eyes MariTide's Next Move
06.08.2025 18:19
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 billion. Also Read: RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program Product sales gr
Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter
06.08.2025 17:18
Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.
Teva’s Ajovy becomes first migraine prevention drug approved for children
06.08.2025 16:58
With the label expansion, Teva gains an edge over rivals Amgen and Eli Lilly in the CGRP inhibitor arena.
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
06.08.2025 12:30
As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for year
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
06.08.2025 11:00
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of exper
Why I Still Don't Think Amgen Is A Buy
06.08.2025 10:56
Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline.
Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...
06.08.2025 07:26
Amgen Inc (AMGN) reports a 9% revenue increase and advances its diverse portfolio with significant sales growth across key products.
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
05.08.2025 12:00
SAN DIEGO, August 05, 2025--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology.
Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
05.08.2025 08:05
The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the mar